Hints and tips:
Related Special Reports
...The crunchy acronym was coined by Goldman Sachs for pharma companies GSK and Roche, Dutch chip company ASML, Switzerland’s Nestlé and Novartis, Danish drugmaker Novo Nordisk, France’s L’Oréal and LVMH, the...
...Publicis Health, a division of the Paris-listed agency, worked with opioid manufacturer Purdue Pharma from 2010 to 2019, creating advertising campaigns and materials to promote opioids including OxyContin...
...Shares in the French pharma company are struggling to recover from their steep fall in October....
French pharma group announces consumer unit split and increased R&D investment
...But pressure is mounting on pharma companies to switch to synthetic substances as populations decline for horseshoe crabs and seabirds that eat the creatures’ eggs....
...However, the company’s big recent launches — including Dupixent, Altuviiio and Beyfortus — were done in partnership with other pharma companies, and the perception among many investors is that Sanofi does...
...The companies best placed to replenish Big Pharma’s pipeline have attracted premium prices. US diabetes drugmaker Provention Bio is a case in point....
...There are more than 2,000 personal injury cases pending against a number of pharma companies that previously sold Zantac. Risinger said Sanofi marketed the drug in the US from 2017 to 2019....
Change comes as French pharma group pours money into immunology and cancer research
...Last year it was the fourth largest spender on lobbying among pharma companies, behind only industry heavyweights Pfizer, Amgen and Roche. Several big firms are benefiting from Illumina’s largesse....
...Iain Simpson, analyst at Barclays, said that following the ruling “we regard Zantac as substantially derisked, leaving Haleon investible again for those without the appetite for pharma litigation risk”....
Shares in French pharma group tumble nearly 6% after blow to pipeline of new treatments
Pharma companies are hoping to catch up with rivals as they report promising trial results for jab
...Sanofi expects to increase profits in the low double digits this year, helped by its blockbuster eczema and asthma drug Dupixent that is at the heart of chief executive Paul Hudson’s plan to overhaul the pharma...
...French pharma group Sanofi has again delayed the expected approval date for its long-awaited Covid-19 vaccine after an oversight body asked it to prolong its late-stage clinical trial....
...The French pharma company is now playing catch-up by investing heavily in the technology used by its more agile challengers Moderna and BioNTech/Pfizer....
French pharma group tries to catch up with rivals that used the technology to create Covid vaccines
...As some analysts float splitting vaccines from the pharma business, Connor argued he works closely with Hal Barron, GSK’s head of research and development, and the businesses have synergies because of the...
...They are priced at 13 times 2021 earnings, compared with an average multiple of 16 times for large European pharma groups. Sanofi’s strategy of buying science, not sales, bodes well for the long term....
...When pharma companies were retrenching 10 years ago, he suspects early stage vaccine programmes were among those cut....
...I do not think that we're going to see the entire pharma industry switch to focusing on vaccines....
French pharma group has two candidates in pipeline
...In such deals, the pharma groups still get paid even if the vaccine does not work....
...“One of the means to that end is to get the health industry and pharma companies in particular to collaborate.”...
Pharma company’s use of algorithms marks fast-growing trend in big digitally-savvy markets including India
International Edition